Logo 1-1.png
Chemomab Therapeutics Announces $10 Million Private Placement
25 juil. 2024 07h38 HE | Chemomab Therapeutics
Chemomab announced a $10 million PIPE that enables the company to extend its cash runway until early 2026, well past 2 upcoming milestones in early 2025.
SPRING Trial: Liver Stiffness Measurements Improved in CM-101-Treated Patients
Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis
25 juil. 2024 07h00 HE | Chemomab Therapeutics
Chemomab reported positive topline results from Ph 2 trial assessing CM-101 in PSC. Achieved safety endpoint and improved wide range of secondary endpoints
Logo 1-1.png
Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis
18 juin 2024 07h00 HE | Chemomab Therapeutics
New publication confirms the role of CCL24 in primary sclerosing cholangitis and the potential of CM-101 to impact PSC disease progression and severity.
Logo 1-1.png
Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference
06 juin 2024 07h00 HE | Chemomab Therapeutics
Chemomab presents new data supporting clinical potential of CM-101 as novel treatment for PSC at EASL 2024 and Gordon Research Conference
Logo 1-1.png
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences
17 mai 2024 07h00 HE | Chemomab Therapeutics
TEL AVIV, Israel, May 17, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for...
Logo 1-1.png
Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
09 mai 2024 07h00 HE | Chemomab Therapeutics
Chemomab reported on major progress in Q1 2024, including that it is on track to report Phase 2 PSC topline data at midyear 2024
Logo 1-1.png
Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
08 mai 2024 07h00 HE | Chemomab Therapeutics
Chemomab has been granted another 180-day extension to regain compliance with the minimum bid price requirement in order to remain listed on Nasdaq.
Logo 1-1.png
Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference
02 mai 2024 07h00 HE | Chemomab Therapeutics
Chemomab CEO Adi Mor will present at the Aegis Virtual Conference on May 7 at 9:00am ET
Logo 1-1.png
Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update
24 avr. 2024 07h00 HE | Chemomab Therapeutics
Chemomab will release its first quarter 2024 financial results and provide a corporate update on May 9, 2024.
Logo 1-1.png
Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis
18 avr. 2024 07h00 HE | Chemomab Therapeutics
Peer-reviewed patient study validates Chemomab's CCL24 as a novel target linked to greater disease severity and higher mortality in systemic sclerosis